A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis
The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.
Key RequirementsClinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.
Have multiple sclerosis (MS)
Have at least 1 documented relapse within the previous year
Have at least 2 documented relapses within the last 2 years
Participants Must Not:
Had a diagnosis of primary progressive MS
Have history of another clinically significant neurological disease
Had a relapse of MS within 30 days prior to randomization
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo